前列腺癌根治性或术后盆腔放疗的剂量提升
回顾性收集意大利六家机构临床淋巴结阳性前列腺癌患者资料,均接受预防性盆腔照射及CT、MRI或胆碱PET/CT检出阳性盆腔淋巴结的推量照射;ISUP分级<2与改善生化无复发生存相关,阳性淋巴结总剂量<60 Gy与更差生化无复发生存相关;治疗设置(术后vs根治性)和推量技术(SIB vs序贯)与生化无复发生存无显著差异。
要点
- ISUP分级<2是改善生化无复发生存的显著预测因素(HR=0.3,95%CI 0.1220-0.7647,P=0.0113)。
- 阳性盆腔淋巴结总剂量<60 Gy与更差生化无复发生存相关(HR=3.59,95%CI 1.3245-9.741,P=0.01)。
- 术后与根治性治疗设置、SIB与序贯推量技术之间生化无复发生存无显著差异。
核心结论
- 盆腔照射及阳性淋巴结推量是有效方法; upfront手术入路未与更好的临床结局相关。
研究设计与样本
- 回顾性分析意大利六家机构临床淋巴结阳性前列腺癌患者资料,均接受预防性盆腔照射及基于CT、MRI或胆碱PET/CT检出阳性盆腔淋巴结的推量照射,探索总生存和生化无复发生存与基线特征的相关性。
诊断标准与关键数值
- ISUP分级<2预测改善生化无复发生存:HR=0.3,95%CI 0.1220-0.7647,P=0.0113。
- 阳性盆腔淋巴结总剂量<60 Gy与更差生化无复发生存相关:HR=3.59,95%CI 1.3245-9.741,P=0.01。
- 术后vs根治性治疗设置与生化无复发生存无显著差异:HR=0.85,95%CI 0.338-2.169,P=0.743。
- SIB vs序贯推量与生化无复发生存无显著差异:HR=2.39,95%CI 0.93-6.111,P=0.067。
临床应用与阅片要点
- 作者认为盆腔照射及阳性淋巴结推量是有效方法, upfront手术入路未与更好临床结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Given the absence of standardized planning approach for clinically node-positive (cN1) prostate cancer (PCa), we collected data about the use of prophylactic pelvic irradiation and nodal boost. The aim of the present series is to retrospectively assess clinical outcomes after this approach to compare different multimodal treatment strategies in this scenario.
METHODS: Data from clinical records of patients affected by cN1 PCa and treated in six different Italian institutes with prophylactic pelvic irradiation and boost on pathologic pelvic lymph nodes detected with CT, MRI or choline PET/CT were retrospectively reviewed and collected. Clinical outcomes in terms of overall survival (OS) and biochemical relapse-free survival (b-RFS) were explored. The correlation between outcomes and baseline features (International Society of Urological Pathology-ISUP pattern, total dose to positive pelvic nodes ≤ / > 60 Gy, sequential or simultaneous integrated boost (SIB) administration and definitive vs postoperative treatment) was explored.
RESULTS: ISUP pattern < 2 was a significant predictor of improved b-RFS (HR = 0.3, 95% CI 0.1220-0.7647, P = 0.0113), while total dose < 60 Gy to positive pelvic nodes was associated with worse b-RFS (HR = 3.59, 95% CI 1.3245-9.741, P = 0.01). Conversely, treatment setting (postoperative vs definitive) and treatment delivery technique (SIB vs sequential boost) were not associated with significant differences in terms of b-RFS (HR = 0.85, 95% CI 0.338-2.169, P = 0.743, and HR = 2.39, 95% CI 0.93-6.111, P = 0.067, respectively).
CONCLUSION: Results from the current analysis are in keeping with data from literature showing that pelvic irradiation and boost on positive nodes are effective approaches. Upfront surgical approach was not associated with better clinical outcomes.
引用
- Francolini, Stocchi, Detti, et al. Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiol Med. 2021. PMID: 34850352. doi:10.1007/s11547-021-01435-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。